• Investing
  • Stock
Round Table Thoughts
  • Economy
  • Editor’s Pick
Home Economy FDA declines approval for Amneal Pharmaceuticals’ Parkinson’s drug
Economy

FDA declines approval for Amneal Pharmaceuticals’ Parkinson’s drug

by July 4, 2023
by July 4, 2023 0 comment
Share
0
FacebookTwitterPinterestWhatsapp

The U.S. Food and Drug Administration (FDA) has declined to approve Amneal Pharmaceuticals’ drug for Parkinson’s disease due to inadequate safety data on the treatment to help control symptoms in patients for a longer duration, the company said on Monday.

Shares of Amneal Pharmaceuticals fell 13.1% to $2.7 in choppy after-market trading.

The FDA in a complete response letter said while the company established the safety of one ingredient, levodopa, based on some studies, it was not able to adequately establish safety for the other ingredient, carbidopa.

The health regulator has requested additional information on the safety of the drug, while it did not identify any efficacy or manufacturing issues with the drug.

Amneal’s drug is a new formulation of carbidopa-levodopa, the standard of care for Parkinson’s, and is designed in a way that allows it to remain in a certain area of the small intestine for a longer period, helping in its consistent absorption.

The company said it will work closely with the health regulator to address the issues and plans to meet with the agency.

The health regulator’s decision is a potential hurdle to the company, which has been looking to grow its portfolio of branded drugs, expecting over $500 million in revenues from its specialty business by 2027.

The drugmaker said the decision does not impact its 2023 financial forecast as it did not include the revenue from the drug.

Amneal currently has another Parkinson’s drug, Rytary, which was approved in 2015 in the market but had been struggling to gain a foothold in the treatment space, with only 4% of patients using it.

Parkinson’s is a brain disorder that causes unintended or uncontrollable movements and is the second most-deadly neurodegenerative disease after Alzheimer’s. There is no cure for Parkinson’s currently, but medicines and other therapies can help relieve symptoms.

<!–>

This post appeared first on FOX NEWS

–>

You Might Also Like
  • Hunter Biden was paid $100K through joint-venture with Chinese energy firm, ex-associate testified
  • Manchin, Tester staff are the least diverse among Senate Democrats, survey finds
  • Border Patrol nabbed 17 people on FBI terror watch list at southern border in December
  • Giuliani mugshot released after he turns himself in on Trump-Georgia 2020 case
Share
0
FacebookTwitterPinterestWhatsapp

previous post
Williamson torches DNC’s ‘outrageous’ support for Biden in 2024 Dem primary
next post
Georgia universities spent millions on DEI efforts prior to state budget cuts: Report

You may also like

Tesla (TSLA) Stocks Up 18% After Strong Earnings

October 25, 2024

House Republicans roll out new election integrity ‘tool kit’ days...

January 11, 2024

Dem strategists insist Biden ‘is a nice person’ despite ‘no...

August 17, 2023

Nvidia Stock Slumps as Dow Futures Edge Lower

November 26, 2024

WV state lawmaker Elliott Pritt switches from Dem to GOP

April 18, 2023

Biden’s Delaware home seen with no Secret Service presence in...

January 17, 2023

Biden climate czar John Kerry likens D-Day invasion to battling...

June 8, 2023

House GOP launches investigation into federally funded news ratings group’s...

June 15, 2024

Comer reveals White House physician was involved in Biden family...

July 7, 2024

Calif Rep Katie Porter’s ex-husband stands by domestic abuse allegations...

April 14, 2023

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Oil prices rise more than 1% as Israel vows to intensify attacks on Iran

      June 20, 2025
    • RRG Alert Tech Vaults to ‘Leading’—Is XLK Signaling a New Rally?

      June 20, 2025
    • Apple looking to make ‘premium’-priced folding iPhones starting next year, analyst says

      June 20, 2025
    • Nike pushes back Skims launch with Kim Kardashian due to production delays

      June 19, 2025
    • The Fed Is Getting It Wrong AGAIN As They Hold Rates Steady

      June 19, 2025

    Popular Posts

    • 1

      Biden appointee played key role in recruiting Chinese...

      June 25, 2024 3,599 views
    • 2

      Trump-era China sanctions ended by Biden may be...

      June 27, 2024 2,875 views
    • 3

      Walz’s honeymoon with China gets fresh scrutiny as...

      August 9, 2024 2,578 views
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful...

      July 10, 2024 2,541 views
    • 5

      Harris VP pick spent years promoting research facility...

      August 29, 2024 2,417 views

    Categories

    • Economy (7,009)
    • Editor's Pick (2,142)
    • Investing (538)
    • Stock (2,621)

    Popular Posts

    • 1

      Biden appointee played key role in recruiting Chinese businesses to Delaware: ‘Longtime friends’

      June 25, 2024
    • 2

      Trump-era China sanctions ended by Biden may be revived under new House GOP bill

      June 27, 2024
    • 3

      Walz’s honeymoon with China gets fresh scrutiny as Harris camp blasts ‘lying’ critics

      August 9, 2024
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful of Chinese spy threats

      July 10, 2024
    • 5

      Harris VP pick spent years promoting research facility that collaborated with ‘Chinese military company’

      August 29, 2024

    Latest News

    • Oil prices rise more than 1% as Israel vows to...

      June 20, 2025
    • RRG Alert Tech Vaults to ‘Leading’—Is XLK Signaling a New...

      June 20, 2025
    • Apple looking to make ‘premium’-priced folding iPhones starting next year,...

      June 20, 2025

    Categories

    • Economy (7,009)
    • Editor's Pick (2,142)
    • Investing (538)
    • Stock (2,621)

    Disclaimer: RoundTableThoughts.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 RoundTableThoughts.com. All Rights Reserved.

    Round Table Thoughts
    • Investing
    • Stock
    Round Table Thoughts
    • Economy
    • Editor’s Pick

    Read alsox

    RNC Chair Ronna McDaniel wins praise...

    August 27, 2023

    The Hitchhiker’s Guide to where we...

    August 15, 2023

    Maine Gov. Janet Mills wants to...

    January 17, 2023
    Sign In

    Keep me signed in until I sign out

    Forgot your password?

    Password Recovery

    A new password will be emailed to you.

    Have received a new password? Login here